Striatal Dopaminergic Fiber Recovery After Acute l-DOPA Treatment in 6-Hydroxydopamine (6-OHDA) Lesioned Rats

Cell Biochemistry and Biophysics

Volumn 59, Issue 1, 2011, Pages 49-56

  Fang, Chuanqin ^a   Yin, Jinbo ^b   Xu, Zhiqiang ^a   Wang, Yanjiang ^a   Xu, Haiwei ^b   Zhou, Huadong ^a   Gao, Changyue ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

6 OHDA; l DOPA; Microglia; Parkinson's disease

Indexed keywords

ANIMALIA; RATTUS;

EID: 78650415502     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-010-9110-3     Document Type: Article

References (22)

1. Chase, T. N., Engber, T. M., & Mouradian, M. M. (1994). Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology, 44, S15-S18.
2. Ebadi, M., & Srinivasan, S. K. (1995). Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacological Reviews, 47, 575-604.
3. Muller, T., Hefter, H., Hueber, R., Jost, W. H., Leenders, K. L., Odin, P., et al. (2004). Is levodopa toxic? Journal of Neurology, 251(Suppl 6), VI/44-VI/46.
4. Naudin, B., Bonnet, J. J., & Costentin, J. (1995). Acute l-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice. Brain Research, 701, 151-157.
5. Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonuccelli, U., Damier, P., et al. (2004). Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders, 19, 997-1005.
6. Tarsy, D., & Baldessarini, R. J. (1984). Tardive dyskinesia. Annual Review of Medicine, 35, 605-623.
7. Datla, K. P., Blunt, S. B., & Dexter, D. T. (2001). Chronic l-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Movement Disorders, 16, 424-434.
8. Dziewczapolski, G., Murer, G., Agid, Y., Gershanik, O., & Raisman-Vozari, R. (1997). Absence of neurotoxicity of chronic l-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport, 8, 975-979.
9. Ferrario, J. E., Taravini, I. R., Mourlevat, S., Stefano, A., Delfino, M. A., Raisman-Vozari, R., et al. (2004). Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. Journal of Neurochemistry, 90, 1348-1358.
10. Murer, M. G., Dziewczapolski, G., Menalled, L. B., Garcia, M. C., Agid, Y., Gershanik, O., et al. (1998). Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Annals of Neurology, 43, 561-575.
11. Group, P. S. (2000). Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA, 284(15), 1931-1938.
12. Nutt, J. G. (2007). Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Movement Disorders, 22, 1-9.
13. Paille, V., Brachet, P., & Damier, P. (2004). Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. Neuroreport, 15, 561-564.
14. Winkler, C., Kirik, D., Bjorklund, A., & Cenci, M. A. (2002). l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiology of Disease, 10, 165-186.
15. Paxinos, G., & Watson, C. (1986). The rat brain in stereotaxic co-ordinates. San Diego: Academic Press.
16. Cenci, M. A., Lee, C. S., & Bjorklund, A. (1998). l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. European Journal of Neuroscience, 10, 2694-2706.
17. Jeon, B. S., Jackson-Lewis, V., & Burke, R. E. (1995). 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration, 4, 131-137.
18. Bowenkamp, K. E., David, D., Lapchak, P. L., Henry, M. A., Granholm, A. C., Hoffer, B. J., et al. (1996). 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Experimental Brain Research, 111, 1-7.
19. Sauer, H., & Oertel, W. H. (1994). Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience, 59, 401-415.
20. Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988). Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature, 334, 345-348.
21. De Vitry, F., Hillion, J., Catelon, J., Thibault, J., Benoliel, J. J., & Hamon, M. (1991). Dopamine increases the expression of tyrosine hydroxylase and aromatic amino acid decarboxylase in primary cultures of fetal neurons. Brain Research. Developmental Brain Research, 59, 123-131.
22. Ferrario, J. E., Delfino, M. A., Stefano, A. V., Zbarsky, V., Douhou, A., Murer, M. G., et al. (2003). Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neuroscience Research, 47, 431-436.